Mark Albrecht, HHS/ASPR/BARDA, to Speak at 13th Anti-Infectives: Partnering & Deal-Making
Mark Albrecht, BARDA, to Present “Expanding Public–Private Partnerships to Strengthen the Antimicrobial Pipeline” at Anti-Infectives Partnering & Deal-Making
San Diego, CA, April 02, 2016 --(PR.com)-- Mark Albrecht, Ph.D., Health Scientist at HHS/ASPR/BARDA will Present “Expanding Public– Private Partnerships to Strengthen the Antimicrobial Pipeline” at GTCbio’s 13th Anti-Infectives: Partnering & Deal-Making Conference (June 2-3, 2016 in San Diego, CA)
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of necessary vaccines, drugs, therapies, and diagnostic tools to prepare the nation to respond to both biodefense and public health emergencies. BARDA’s utilization of novel public – private partnerships bridge corporate funding gaps while mitigating research and development risks that would otherwise result in early project attrition.
Through the use of non-dilutive funding, BARDA’s Antibacterials program incentivizes the antimicrobial product pipeline with the goal to increase ongoing research and development of both broad and narrow spectrum products that are effective against biodefense pathogens as well as antimicrobial resistant bacterial pathogens. The 2015 National Action Plan for Combating Antibiotic-Resistant Bacteria afforded BARDA’s AI program a broader mandate to fund the development of antimicrobials, non-traditional therapies, and diagnostic tests. This impactful change has the potential to increase the robustness of the developmental pipeline to address antimicrobial resistance and public health indications.
GTCbio’s 13th Anti-Infectives: Partnering & Deal-Making Conference as we discuss and seek to answer questions such as, how can we better price antibiotics so that their value to society is better reflected and companies get a better ROI? What has caused the re-emergence of large pharmaceutical companies back into this space and how will that affect the other players? How have FDA guidelines changed and how will that change development? Leaders in the field will provide updates, and dedicated networking sessions will allow colleagues to form connections in an accessible and intimate environment.
This conference is also part of the larger Infectious Diseases World Summit, which consists of 4 total conferences:
14th Vaccines Research & Development
13th Anti-Infectives Partnering & Deal-Making
5th Antiviral Drugs Research & Development
2nd Bugs & Drugs: Antibacterial Drug Discovery
For more information, please visit the website: http://www.gtcbio.com/anti-infectives
GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433
The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of necessary vaccines, drugs, therapies, and diagnostic tools to prepare the nation to respond to both biodefense and public health emergencies. BARDA’s utilization of novel public – private partnerships bridge corporate funding gaps while mitigating research and development risks that would otherwise result in early project attrition.
Through the use of non-dilutive funding, BARDA’s Antibacterials program incentivizes the antimicrobial product pipeline with the goal to increase ongoing research and development of both broad and narrow spectrum products that are effective against biodefense pathogens as well as antimicrobial resistant bacterial pathogens. The 2015 National Action Plan for Combating Antibiotic-Resistant Bacteria afforded BARDA’s AI program a broader mandate to fund the development of antimicrobials, non-traditional therapies, and diagnostic tests. This impactful change has the potential to increase the robustness of the developmental pipeline to address antimicrobial resistance and public health indications.
GTCbio’s 13th Anti-Infectives: Partnering & Deal-Making Conference as we discuss and seek to answer questions such as, how can we better price antibiotics so that their value to society is better reflected and companies get a better ROI? What has caused the re-emergence of large pharmaceutical companies back into this space and how will that affect the other players? How have FDA guidelines changed and how will that change development? Leaders in the field will provide updates, and dedicated networking sessions will allow colleagues to form connections in an accessible and intimate environment.
This conference is also part of the larger Infectious Diseases World Summit, which consists of 4 total conferences:
14th Vaccines Research & Development
13th Anti-Infectives Partnering & Deal-Making
5th Antiviral Drugs Research & Development
2nd Bugs & Drugs: Antibacterial Drug Discovery
For more information, please visit the website: http://www.gtcbio.com/anti-infectives
GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433
Contact
GTCbio
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
fax: 626-466-4433
Kristen Starkey
626-256-6405
http://www.gtcbio.com
635 W. Foothill Blvd.
Monrovia, CA 91016
fax: 626-466-4433
Contact
Categories